Atopic Dermatitis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Atopic Dermatitis – Pipeline Review, H1 2018’, provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis

– The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects

– The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Abeome Corp

Accolade Pharmaceuticals LLC

Aclaris Therapeutics Inc

Allergan Plc

Amgen Inc

Amorepacific Corp

AnaptysBio Inc

Antibiotx ApS

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Bioleaders Corp

Blueberry Therapeutics Ltd

Brickell Biotech Inc

Celgene Corp

ChironWells GmbH

Chugai Pharmaceutical Co Ltd

Clevexel Pharma SAS

Cutanea Life Sciences Inc

Dermala Inc

DURECT Corp

Eli Lilly and Co

Exicure Inc

F. Hoffmann-La Roche Ltd

Fountain Biopharma Inc

Galapagos NV

Galderma SA

Galectin Therapeutics Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Han Wha Pharma Co Ltd

Heptares Therapeutics Ltd

iCo Therapeutics Inc.

Immune Pharmaceuticals Inc

Incyte Corp

Inflamalps SA

Innovation Pharmaceuticals Inc

Japan Tobacco Inc

Kang Stem Biotech Co Ltd

KPI Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Lead Pharma Holding BV

LEO Pharma A/S

Madam Therapeutics BV

MedImmune LLC

NeoPharm Co Ltd

Novan Inc

Novartis AG

Nuevolution AB

Orbis Biosciences Inc

Otsuka Holdings Co Ltd

Oxagen Ltd

Pfizer Inc

Pharis Biotec GmbH

Pharmedartis GmbH

Qurient Co Ltd

Realm Therapeutics Plc

Regeneron Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Signum Biosciences Inc

Spherium Biomed SL

sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd

Switch Biotech LLC

TaiwanJ Pharmaceuticals Co Ltd

Thesan Pharmaceuticals Inc

Torrent Pharmaceuticals Ltd

Valeant Pharmaceuticals International Inc

VivaCell Biotechnology Espana SL

Xencor Inc

Zhejiang I-Biological Technology Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Atopic Dermatitis Overview 7

Atopic Dermatitis Therapeutics Development 8

Atopic Dermatitis Therapeutics Assessment 25

Atopic Dermatitis Companies Involved in Therapeutics Development 37

Atopic Dermatitis Drug Profiles 68

Atopic Dermatitis Dormant Projects 345

Atopic Dermatitis Discontinued Products 352

Atopic Dermatitis Product Development Milestones 354

Appendix 365

List of Tables

List of Tables

Number of Products under Development for Atopic Dermatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Atopic Dermatitis Pipeline by AbbVie Inc, H1 2018

Atopic Dermatitis Pipeline by Abeome Corp, H1 2018

Atopic Dermatitis Pipeline by Accolade Pharmaceuticals LLC, H1 2018

Atopic Dermatitis Pipeline by Aclaris Therapeutics Inc, H1 2018

Atopic Dermatitis Pipeline by Allergan Plc, H1 2018

Atopic Dermatitis Pipeline by Amgen Inc, H1 2018

Atopic Dermatitis Pipeline by Amorepacific Corp, H1 2018

Atopic Dermatitis Pipeline by AnaptysBio Inc, H1 2018

Atopic Dermatitis Pipeline by Antibiotx ApS, H1 2018

Atopic Dermatitis Pipeline by Asana BioSciences LLC, H1 2018

Atopic Dermatitis Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Atopic Dermatitis Pipeline by Bioleaders Corp, H1 2018

Atopic Dermatitis Pipeline by Blueberry Therapeutics Ltd, H1 2018

Atopic Dermatitis Pipeline by Brickell Biotech Inc, H1 2018

Atopic Dermatitis Pipeline by Celgene Corp, H1 2018

Atopic Dermatitis Pipeline by ChironWells GmbH, H1 2018

Atopic Dermatitis Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Atopic Dermatitis Pipeline by Clevexel Pharma SAS, H1 2018

Atopic Dermatitis Pipeline by Cutanea Life Sciences Inc, H1 2018

Atopic Dermatitis Pipeline by Dermala Inc, H1 2018

Atopic Dermatitis Pipeline by DURECT Corp, H1 2018

Atopic Dermatitis Pipeline by Eli Lilly and Co, H1 2018

Atopic Dermatitis Pipeline by Exicure Inc, H1 2018

Atopic Dermatitis Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Atopic Dermatitis Pipeline by Fountain Biopharma Inc, H1 2018

Atopic Dermatitis Pipeline by Galapagos NV, H1 2018

Atopic Dermatitis Pipeline by Galderma SA, H1 2018

Atopic Dermatitis Pipeline by Galectin Therapeutics Inc, H1 2018

Atopic Dermatitis Pipeline by GlaxoSmithKline Plc, H1 2018

Atopic Dermatitis Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018

Atopic Dermatitis Pipeline by Han Wha Pharma Co Ltd, H1 2018

Atopic Dermatitis Pipeline by Heptares Therapeutics Ltd, H1 2018

Atopic Dermatitis Pipeline by iCo Therapeutics Inc., H1 2018

Atopic Dermatitis Pipeline by Immune Pharmaceuticals Inc, H1 2018

Atopic Dermatitis Pipeline by Incyte Corp, H1 2018

Atopic Dermatitis Pipeline by Inflamalps SA, H1 2018

Atopic Dermatitis Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Atopic Dermatitis Pipeline by Japan Tobacco Inc, H1 2018

Atopic Dermatitis Pipeline by Kang Stem Biotech Co Ltd, H1 2018

Atopic Dermatitis Pipeline by KPI Therapeutics Inc, H1 2018

Atopic Dermatitis Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Atopic Dermatitis Pipeline by Lead Pharma Holding BV, H1 2018

Atopic Dermatitis Pipeline by LEO Pharma A/S, H1 2018

Atopic Dermatitis Pipeline by Madam Therapeutics BV, H1 2018

Atopic Dermatitis Pipeline by MedImmune LLC, H1 2018

Atopic Dermatitis Pipeline by NeoPharm Co Ltd, H1 2018

Atopic Dermatitis Pipeline by Novan Inc, H1 2018

Atopic Dermatitis Pipeline by Novartis AG, H1 2018

Atopic Dermatitis Pipeline by Nuevolution AB, H1 2018

Atopic Dermatitis Pipeline by Orbis Biosciences Inc, H1 2018

Atopic Dermatitis Pipeline by Otsuka Holdings Co Ltd, H1 2018

Atopic Dermatitis Pipeline by Oxagen Ltd, H1 2018

Atopic Dermatitis Pipeline by Pfizer Inc, H1 2018

Atopic Dermatitis Pipeline by Pharis Biotec GmbH, H1 2018

Atopic Dermatitis Pipeline by Pharmedartis GmbH, H1 2018

Atopic Dermatitis Pipeline by Qurient Co Ltd, H1 2018

Atopic Dermatitis Pipeline by Realm Therapeutics Plc, H1 2018

Atopic Dermatitis Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Atopic Dermatitis Pipeline by Sienna Biopharmaceuticals Inc, H1 2018

Atopic Dermatitis Pipeline by Signum Biosciences Inc, H1 2018

Atopic Dermatitis Pipeline by Spherium Biomed SL, H1 2018

Atopic Dermatitis Pipeline by sterna biologicals Gmbh & Co KG, H1 2018

Atopic Dermatitis Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Atopic Dermatitis Pipeline by Switch Biotech LLC, H1 2018

Atopic Dermatitis Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2018

Atopic Dermatitis Pipeline by Thesan Pharmaceuticals Inc, H1 2018

Atopic Dermatitis Pipeline by Torrent Pharmaceuticals Ltd, H1 2018

Atopic Dermatitis Pipeline by Valeant Pharmaceuticals International Inc, H1 2018

Atopic Dermatitis Pipeline by VivaCell Biotechnology Espana SL, H1 2018

Atopic Dermatitis Pipeline by Xencor Inc, H1 2018

Atopic Dermatitis Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2018

Atopic Dermatitis Dormant Projects, H1 2018

Atopic Dermatitis Dormant Projects, H1 2018 (Contd..1), H1 2018

Atopic Dermatitis Dormant Projects, H1 2018 (Contd..2), H1 2018

Atopic Dermatitis Dormant Projects, H1 2018 (Contd..3), H1 2018

Atopic Dermatitis Dormant Projects, H1 2018 (Contd..4), H1 2018

Atopic Dermatitis Dormant Projects, H1 2018 (Contd..5), H1 2018

Atopic Dermatitis Dormant Projects, H1 2018 (Contd..6), H1 2018

Atopic Dermatitis Discontinued Products, H1 2018

Atopic Dermatitis Discontinued Products, H1 2018 (Contd..1), H1 2018

List of Figures

List of Figures

Number of Products under Development for Atopic Dermatitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports